{"id":"W4392151488","doi":"10.1159/000537947","title":"Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Astellas Pharma; Eisai; Plexxikon; Seagen; Pfizer; NuCana; Incyte; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; EA Pharma Co., Ltd.; Merck KGaA; Baxalta; Sirtex Medical; Cancer Research UK; Boston Scientific Corporation; Halozyme; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Medicine; Sorafenib; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Randomized controlled trial; Overall survival; Radiology; Clinical trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005065583,0.0002142141,0.0006172727,0.0003122234,0.00002970351,0.00003314916,0.00008262148,0.0000571045,0.0001659673],"category_scores_gemma":[0.00004060847,0.000112824,0.00009080848,0.0008856495,0.00009459822,0.0001408228,0.00001128649,0.0001698434,0.00000366133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001315061,"about_ca_system_score_gemma":0.0002704867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001596232,"about_ca_topic_score_gemma":0.0001270162,"domain_scores_codex":[0.9982491,0.0004516082,0.0003781946,0.0003123634,0.0003755065,0.0002332448],"domain_scores_gemma":[0.9992623,0.0002499085,0.0001072196,0.0002435034,0.00009179506,0.00004525173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4606043,0.0004215738,0.5351844,0.0001229177,0.00009619472,0.0003725279,0.0009811147,2.451095e-7,0.001652499,0.00001277315,0.000008497802,0.0005429397],"study_design_scores_gemma":[0.8448542,0.003556732,0.120804,0.0009227816,0.0006296606,0.000007695547,0.00005620738,0.003273163,0.02529629,0.000004262873,0.000387391,0.0002075837],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943978,0.001056145,0.00001460421,0.0001766647,0.00004367347,0.0040179,0.00006513738,0.00003158375,0.0001965531],"genre_scores_gemma":[0.9980798,0.00009945847,0.00003806967,0.00009899084,0.00005149013,0.001022208,0.0002567022,0.00003629804,0.0003170159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4143805,"threshold_uncertainty_score":0.4600829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04313391345594417,"score_gpt":0.2807608521821021,"score_spread":0.2376269387261579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}